Generically known as sacubitril valsartan, nosintrex is usually required for life after stenting; when discomfort develops, it is recommended to visit the doctor and, if necessary, to gradually discontinue the medication. Sacubitril valsartan belongs to a combination of preparations, which are mainly used in the treatment of chronic heart failure with reduced ejection fraction and other diseases, but also reduces the risk of cardiovascular death and re-hospitalization for heart failure; the use of this drug after stenting reduces the volume load on the heart, improves the coronary blood flow, and relieves the symptoms of cardiac insufficiency. Sacubitril valsartan can also inhibit myocardial remodeling, improve myocardial hypertrophy, and slow the progression of heart failure; the drug usually needs to be taken for life to achieve a more desirable therapeutic effect; if abnormalities of serum creatinine and serum potassium occur after taking the drug, it is necessary to go to the hospital, and discontinue the drug in a gradual manner if necessary. The drug may also cause abnormal hemoglobin and erythrocyte pressure index, as well as cerebrovascular edema and other discomforts; for severe hepatic impairment, biliary cirrhosis, severe renal insufficiency, pregnant women are prohibited; in the process of using the drug also need to monitor the electrolytes, liver function, etc., and for breastfeeding women, children, the elderly and other special populations, the need to comply with the instructions of the doctor to use the drug. The above medication is recommended to be used under the guidance of a doctor to avoid self-medication, which may lead to adverse consequences.